Literature DB >> 8300361

Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease.

K Norose1, A Yano, X C Wang, T Tokushima, J Umihira, A Seki, M Nohara, K Segawa.   

Abstract

PURPOSE: To determine the immunopathologic role of the lymphocytes and lymphokines in aqueous humor (AH) of patients with Vogt-Koyanagi-Harada disease (VKH).
METHODS: The distribution of leukocyte subsets in the peripheral blood and AH was examined using fluorescein isothiocyanate-conjugated monoclonal antibodies. The levels of lymphokines, such as interleukin-2 (IL-2) and interleukin-6 (IL-6), in the sera, AH, and cerebrospinal fluid from the patients with VKH were determined using an enzyme-linked immunosorbent assay.
RESULTS: T cells constituted the majority of lymphocytes within AH. The value for CD4+ cells (helper/inducer T lymphocytes) in AH was 51.7% +/- 14.9% (mean +/- SD) and that for CD8+ cells (cytotoxic/suppressor T lymphocytes) was 31.1% +/- 13.0%. The percentage of HLA-DR+ cells (B lymphocytes, monocytes, macrophages, and activated T lymphocytes) in AH (50.8% +/- 24.9%) significantly exceeded (P < 0.001) that in blood (13.1% +/- 4.2%). The percentage of CD8+ cells in AH from three patients with the delayed type of VKH rose during their clinical course. The level of IL-6 was significantly elevated in AH from the patients with VKH. The level of IL-6 in AH correlated with the number of lymphocytes in AH, and it reflected the severity of the inflammatory response in AH of patients with VKH. The level of IL-2 in the sera, AH, and cerebrospinal fluid was in the normal range.
CONCLUSIONS: Aqueous humor lymphocytes from the patients with VKH were more activated than were peripheral blood lymphocytes. IL-6 may play an important role as an inflammatory mediator in VKH. It may be useful to analyze the lymphocyte subsets and the levels of lymphokines, especially of IL-6, at the site of inflammation in uvea to improve the criteria for assessing the prognosis of VKH.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8300361

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  18 in total

Review 1.  Advances in the diagnosis and immunotherapy for ocular inflammatory disease.

Authors:  Steven Yeh; Lisa J Faia; Robert B Nussenblatt
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

Review 2.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

3.  Molecular analysis of resolving immune responses in uveitis.

Authors:  P I Murray; C D Clay; C Mappin; M Salmon
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

4.  Upregulation of T-bet expression in peripheral blood mononuclear cells during Vogt-Koyanagi-Harada disease.

Authors:  B Li; P Yang; H Zhou; X Huang; H Jin; L Chu; Y Gao; L Zhu; A Kijlstra
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

5.  The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet's uveitis.

Authors:  H G Yu; D S Lee; J M Seo; J K Ahn; Y S Yu; W J Lee; H Chung
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

6.  Development of fully automated anterior chamber cell analysis based on image software.

Authors:  Tae Seen Kang; Yeongseop Lee; Seongjin Lee; Kyonghoon Kim; Woong-Sub Lee; Woohyuk Lee; Jin Hyun Kim; Yong Seop Han
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

7.  Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8.

Authors:  Siavash Toosi; Seth J Orlow; Prashiela Manga
Journal:  J Invest Dermatol       Date:  2012-06-14       Impact factor: 8.551

Review 8.  Ocular complications of childhood rheumatic diseases: uveitis.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2006-12       Impact factor: 4.686

9.  High dose infliximab in the treatment of refractory uveitis: does dose matter?

Authors:  Sukesh Sukumaran; Katherine Marzan; Bracha Shaham; Andreas Reiff
Journal:  ISRN Rheumatol       Date:  2012-01-05

Review 10.  miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease.

Authors:  Fabian Vega-Tapia; Mario Bustamante; Rodrigo A Valenzuela; Cristhian A Urzua; Loreto Cuitino
Journal:  Front Cell Dev Biol       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.